<--GAT-->
Clinical Topics

Overcoming Radiation Resistant Prostate Cancer

by U.S. Medicine

April 23, 2019

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery.

The problem is that nearly 30% to 50% of patients undergoing radiotherapy develop radiation-resistant disease, according to a study in the journal Oncogene.1

A research team from the Los Angeles VAMC and Cedars-Sinai Medical Center suggested that better understanding of mechanisms that lead to radiation resistance could aid in the development of sensitizing agents to improve outcome.

The researchers identified a radiation-resistance pathway mediated by CD105, downstream of BMP and TGF-β signaling. They found that antagonizing CD105-dependent BMP signaling with a partially humanized monoclonal antibody, TRC105, resulted in a significant reduction in clonogenicity when combined with irradiation.

“In trying to better understand the mechanism for the radio-sensitization, we found that radiation-induced CD105/BMP signaling was sufficient and necessary for the upregulation of sirtuin 1 (SIRT1) in contributing to p53 stabilization and PGC-1α activation,” they wrote. “Combining TRC105 with irradiation delayed DNA damage repair compared to irradiation alone. However, in the absence of p53 function, combining TRC105 and radiation resulted in no reduction in clonogenicity compared to radiation alone, despite similar reduction of DNA damage repair observed in p53-intact cells.”

The authors said this finding “suggested DNA damage repair was not the sole determinant of CD105 radio-resistance.”

Cancer cells undergo an energy deficit following irradiation, due to the demands of DNA and organelle repair, and the study examined SIRT1’s role on p53 and PGC-1α in terms of glycolysis and mitochondrial biogenesis, respectively. Researchers determined that blocking the CD105-SIRT1 axis depleted the ATP stores of irradiated cells and caused G2 cell cycle arrest.

Xenograft models supported these findings that combining TRC105 with irradiation significantly reduces tumor size over irradiation alone (p value = 10-9), according to the authors, who concluded, “We identified a novel synthetic lethality strategy of combining radiation and CD105 targeting to address the DNA repair and metabolic addiction induced by irradiation in p53-functional prostate cancers.”

Madhav A, Andres A, Duong F, Mishra R, Haldar S, Liu Z, Angara B, Gottlieb R, Zumsteg ZS, Bhowmick NA. Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene. 2018 Aug;37(32):4385-4397. doi: 10.1038/s41388-018-0278-0. Epub 2018 May 2. PubMed PMID: 29717261; PubMed Central PMCID: PMC6085281.



Related Articles

Technology Experts Question MISSION Act Electronic Systems

WASHINGTON—VA is working under a tight deadline to implement the community care provisions of the MISSION Act, the new law that goes into effect this summer and revises and codifies access standards for veterans receiving... View Article

VA Study Raises Questions About Value of Readmission Metrics

SAN FRANCISCO—While the VA performs well overall on key 30-day readmission rates, a study by researchers at the San Francisco VAMC questioned the utility of the measures for most of the health system’s hospitals. The... View Article


U.S. Medicine Recommends


More From oncology

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

WASHINGTON—High turnover among leadership, gaps in accountability, and long-standing problems in cybersecurity represent significant challenges for VA in its ongoing efforts to improve its IT infrastructure, oversight officials told legislators last month. These challenges will... View Article

Oncology

Response of Veterans to PD-1 Checkpoint Inhibitors

WASHINGTON—High turnover among leadership, gaps in accountability, and long-standing problems in cybersecurity represent significant challenges for VA in its ongoing efforts to improve its IT infrastructure, oversight officials told legislators last month. These challenges will... View Article

Oncology

Surgical Staging Often Inadequate for Gallbladder Cancer

Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.

Oncology

Use of Hospice During Treatment Has Limited VA Use

Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.

Oncology

Hypertension, MGUS Associated with Herbicide Exposure in Vietnam Veterans

Based on a new review, two conditions–one extremely common and the other rare–appear to be related to herbicide exposure during the Vietnam War era.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up